Changes in Th17 cells frequency and function after ozone therapy used to treat multiple sclerosis patients
Izadi M, Tahmasebi S, Pustokhina I, et al. Multiple Sclerosis and Related Disorders, 2020.
- Study type
- Case series
- People studied
- 20 people
- Population
- Multiple sclerosis patients
- Published
- 2020, Multiple Sclerosis and Related Disorders
- Identifiers
- PMID 32862036, DOI 10.1016/j.msard.2020.102466
What the authors reported
In 20 MS patients, the authors' own "non-controlled study" found ozone autohemotherapy lowered the frequency of pro-inflammatory Th17 cells and related markers after treatment compared with before.
What limits this result
The authors describe it as non-controlled; a before-after comparison in one treated group measuring a laboratory immune marker rather than disability or symptom outcomes.
How ozone acts on blood and cells, how blood filters work, the laboratory and device-development studies behind the EBOO circuit, and studies that measure markers in the blood rather than how patients fare. None of these shows whether EBO2 helps patients. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
How the study was done
- Design
- Non-controlled study (authors' wording) of ozone autohemotherapy in multiple sclerosis patients
The current non-controlled study aimed to evaluate the therapeutic implications of ozone autohemotherapy on Th17 responses in MS patients.
- Setting
- Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
- Read from
- Read from the abstract only; where this page says nothing about an item, the abstract does not report it. Read on September 28, 2026.
Source: Abstract on PubMed
Study arms
| Group | Participants | What they received |
|---|---|---|
| MS patients (experimental group) | 20 | Ozone autohemotherapy: 100 ml of O2/O3 (25 ugs/ml) with 100 ml of autologous blood, twice per week for 6 months |
| Control group(s) | Not reported | Not described in the abstract; patients were compared with control groups |
Source: Abstract on PubMed
Procedure as reported
- Ozone concentration
- 25 ugs/ml
- Blood volume
- 100 ml of autologous blood
- Sessions
- Twice per week for 6 months
In the paper's own units, not converted.
Source: Abstract on PubMed
What it measured
- Frequency of Th17 cells, post- versus pre-treatment
- Significant decrease (P = 0.0002)
- Expression of RORɣt and IL-17, post- versus pre-treatment
- Significant decrease (P = 0.0001 and P = 0.0004, respectively)
- Expression of miR-141 and miR-155, post- versus pre-treatment
- Significant decrease (P<0.0001 and P<0.0001, respectively)
- Secretion level of IL-17 in treated patients
- Significant reduction (P = 0.043)
Source: Abstract on PubMed
Funding and conflicts
Europe PMC's funding section lists Baqiyatallah University of Medical Sciences as a funder; no funding or conflict statement appears in the abstract
Source: Abstract on Europe PMC
Where we cite this study
Does EBO2 (EBOO) Work? The Evidence, Study by Study
Every study in our EBO2 (EBOO) library in one place: design, size, what was measured and found, its limits, and a check for any study a clinic cites.
EBO2 (EBOO) for Autoimmune Conditions: Clinic Claims, the MS and Sjögren's Studies, and Standard Care
What clinics claim about EBO2 (EBOO) for autoimmune disease, what the MS, Sjögren's and RA ozone studies measured, and what NIH describes as care.
How Many EBO2 (EBOO) Sessions Do You Need? What Clinics Recommend and What Studies Used
How many EBO2 (EBOO) sessions US clinics recommend, from our dataset of clinic pages, set against the course lengths published studies actually used.